TPG-backed Immucor buys Sentilus

Immucor, a portfolio company of TPG, has acquired Sentilus. No financial terms were disclosed. Ropes & Gray advised Immucor on the transaction. Based in Durham, NC, Sentilus is a provider of microarray-based technology used in a variety of in vitro diagnostics areas.

PRESS RELEASE

Ropes & Gray advised TPG-backed Immucor, a leading transfusion and transplantation diagnostics company, in its acquisition of Sentilus, Inc. Durham, N.C.-based Sentilus is the developer of a novel microarray-based technology called Femtoarrays™ for use in a variety of in vitro diagnostics areas. The transaction was announced Oct. 1.

The Ropes & Gray team was led by private equity partner Neill Jakobe (Chicago) and included tax partner Aaron Harsh (Boston), labor & employment partner Peter Ebb (Boston), finance partner Alexander Zeltser (New York) and health care counsel Alison Fethke (Chicago).